Foghorn Therapeutics Files 8-K

Ticker: FHTX · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateOct 10, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-disclosure

TL;DR

Foghorn Therapeutics filed an 8-K on 10/10/24 covering Reg FD, other events, and financials.

AI Summary

Foghorn Therapeutics Inc. filed an 8-K on October 10, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Cambridge, MA.

Why It Matters

This 8-K filing provides updates on Foghorn Therapeutics' corporate activities, including regulatory disclosures and financial information, which are important for investors to monitor.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse events.

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — Registrant
  • October 10, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Cambridge, MA (location) — Principal executive office address

FAQ

What is the primary purpose of this 8-K filing for Foghorn Therapeutics Inc.?

This 8-K filing serves as a Current Report for Foghorn Therapeutics Inc., covering items related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on October 10, 2024.

In which state is Foghorn Therapeutics Inc. incorporated?

Foghorn Therapeutics Inc. is incorporated in Delaware.

What is the principal executive office address of Foghorn Therapeutics Inc.?

The principal executive office address of Foghorn Therapeutics Inc. is 500 Technology Square, Suite 700, Cambridge, MA 02139.

What is the Standard Industrial Classification (SIC) code for Foghorn Therapeutics Inc.?

The Standard Industrial Classification (SIC) code for Foghorn Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-10-10 07:15:50

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Foghorn Therapeutics Inc. (the "Company") is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a presentation, dated October 2024, which the Company plans to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Information

Item 8.01 Other Information. On October 10, 2024, the Company issued a press release announcing the first patient dosed with FHD-909 (LY4050784) in the Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target patient population. A copy of the Company's press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Invest or Presen tation dated October 2024 99.2 Press release issued on October 10 , 202 4

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Kristian Humer Kristian Humer Chief Financial Officer Date: October 10, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.